Israeli-American privately held biomed company Chiasma announced the pricing of its initial public offering of 6, 365, 000 shares of common stock at a price of $16.00 per share, before underwriting discounts.
All of the common stock is being offered by Chiasma. In addition, Chiasma has granted the underwriters a 30-day option to purchase up to 954, 750 additional shares of common stock at the public offering price, before underwriting discounts. Chiasma’s shares are expected to begin trading on The NASDAQ Global Select Market on Thursday, July 16, 2015, under the ticker symbol “CHMA.”
Barclays Capital Inc. and Cowen and Company, LLC acted as joint book-running managers for the offering. William Blair & Company, L.L.C. and Oppenheimer & Co. Inc. acted as co-managers.
The company, which recently submitted a request for marketing approval of its drug for treatment of acromegaly, a disease stemming from excessive hormone growth, will raise $80 million, and up to $92 million if the underwriters options are realized. Barclays Capital and Cowen & Co. are leading the offering with William Blair and Oppenheimer as the secondary underwriters
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on July 15, 2015.